EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Personalized treatment approach for HER2-positive metastatic breast cancer

Prashant Pandey, Rishabh Chaudhary, Devika Tripathi, Kousalya Lavudi, Kamal Dua, Michael Weinfeld, Afsaneh Lavasanifar, P S Rajinikanth

Medical Oncology · 2024

DOI: 10.1007/s12032-024-02504-4 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Medical Oncology, 2024. Verfasst von Prashant Pandey und 7 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, T6G 2H7, Canada. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Precision Medicine. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 144 Literaturangaben. Gefördert von: Science and Engineering Research Board.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer (BC) is a leading global concern for women, with 30% being HER2-positive cases linked to poorer outcomes. Targeted therapies like trastuzumab deruxtecan (T-DXd), trastuzumab, pertuzumab, and T-DM1 have revolutionized HER2-positive metastatic breast cancer (MBC) treatment. Although these therapies have improved MBC management and patient outcomes, resistance can develop, reducing effectiveness. Personalized strategies based on tumor characteristics offer hope for better responses and longer outcomes. This review outlines insights into MBC patients responding well to anti-HER2 treatments, even across multiple treatment regimen. Recent immunotherapy, locoregional therapy, and liquid biopsy breakthroughs are covered, suggesting ways to increase long-term responders. Personalized approaches have boosted HER2-positive MBC outcomes, and ongoing research is crucial to uncover new treatments and biomarkers, potentially elevating long-term response rates and prognoses. This may aid in providing new direction to breast cancer clinics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesPrecision MedicineHumansFemaleNeoplasm MetastasisAntineoplastic Agents, ImmunologicalMolecular Targeted TherapyBiomarkers, TumorAntineoplastic Combined Chemotherapy ProtocolsImmunotherapy

Stichwörter der Autor:innen

Anti-HER2Breast cancerHER2ImmunotherapyLiquid biopsyLocoregional

Substanzen

Erb-b2 Receptor Tyrosine KinasesAntineoplastic Agents, ImmunologicalBiomarkers, TumorERBB2 protein, human

Autor:innen und Institutionen

  • Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, T6G 2H7, Canada.
  • Department of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University, Lucknow, Uttar Pradesh, 226025, India.
  • PSIT-Pranveer Singh Institute of Technology (Pharmacy), Kanpur, India.
  • Department of Radiation Oncology, College of Medicine, The Ohio State University, Columbus, OH, 43210, USA.
  • Comprehensive Cancer Center, The Ohio State University, Columbus, OH, 43210, USA.
  • Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW, 2007, Australia.

Förderung

  • Science and Engineering Research Board

Zitieren

APA

Pandey, P., Chaudhary, R., Tripathi, D., Lavudi, K., Dua, K., Weinfeld, M., Lavasanifar, A., & Rajinikanth, P. S. (2024). Personalized treatment approach for HER2-positive metastatic breast cancer. Medical Oncology. https://doi.org/10.1007/s12032-024-02504-4

Vancouver

Pandey P, Chaudhary R, Tripathi D, Lavudi K, Dua K, Weinfeld M, et al. Personalized treatment approach for HER2-positive metastatic breast cancer. Medical Oncology. 2024. doi:10.1007/s12032-024-02504-4

BibTeX
@article{Pandey2024,
  author = {Pandey, Prashant and Chaudhary, Rishabh and Tripathi, Devika and Lavudi, Kousalya and Dua, Kamal and Weinfeld, Michael and Lavasanifar, Afsaneh and Rajinikanth, P S},
  title = {Personalized treatment approach for HER2-positive metastatic breast cancer},
  journal = {Medical Oncology},
  year = {2024},
  doi = {10.1007/s12032-024-02504-4}
}
Kostenlos starten →